Xavier Mariette
#100,179
Most Influential Person Now
Researcher
Xavier Mariette's AcademicInfluence.com Rankings
Xavier Mariettebiology Degrees
Biology
#4972
World Rank
#7330
Historical Rank
Immunology
#218
World Rank
#227
Historical Rank
Neuroscience
#548
World Rank
#570
Historical Rank
Download Badge
Biology
Xavier Mariette's Degrees
- PhD Biomedical Sciences Université Paris Cité
- Masters Immunology University of Oxford
- Bachelors Biology Université Paris Cité
Similar Degrees You Can Earn
Why Is Xavier Mariette Influential?
(Suggest an Edit or Addition)Xavier Mariette's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) (2474)
- Genetics of rheumatoid arthritis contributes to biology and drug discovery (2013) (1877)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013) (1711)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update (2020) (1453)
- 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts (2017) (1276)
- 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus (2019) (936)
- Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. (2002) (800)
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome (2009) (727)
- 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome (2016) (662)
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. (2020) (624)
- Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. (2009) (619)
- FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries (2014) (611)
- The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome (2003) (566)
- Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. (2006) (565)
- Treat-to-target in systemic lupus erythematosus: recommendations from an international task force (2014) (526)
- High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. (1998) (518)
- Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. (2009) (514)
- Primary Sjögren's Syndrome (2018) (466)
- Sjögren syndrome (2023) (442)
- Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). (2004) (437)
- Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases (2004) (419)
- 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus (2019) (419)
- Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. (2002) (416)
- Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome (2013) (411)
- A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases (2003) (395)
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis (2011) (391)
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. (2021) (391)
- Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey (2005) (389)
- Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. (2010) (379)
- EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome (2011) (373)
- High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. (2005) (369)
- Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis (2011) (364)
- Immune-related adverse events of checkpoint inhibitors (2020) (360)
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective (2012) (344)
- Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome (2006) (302)
- Advances in understanding the pathogenesis of primary Sjögren's syndrome (2013) (295)
- Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials (2017) (283)
- Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry (2010) (281)
- Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study (2017) (262)
- Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. (2010) (261)
- A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) (2016) (259)
- B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome (2006) (258)
- Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. (2015) (258)
- Lymphomas in Patients With Sjögren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses (1997) (241)
- Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. (2014) (236)
- EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide (2015) (236)
- Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force (2016) (235)
- Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI) (2014) (231)
- Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. (2003) (228)
- Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity (2009) (226)
- EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies (2019) (221)
- Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI) (2014) (220)
- Sjögren Syndrome‐associated lymphomas: an update on pathogenesis and management (2015) (217)
- Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial (2007) (211)
- Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. (2015) (211)
- EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 (2020) (208)
- Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial (2013) (203)
- Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry (2009) (203)
- Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? (2005) (199)
- Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry (2012) (195)
- Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome (2004) (191)
- Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. (2007) (188)
- Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment (2017) (188)
- Tumour necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases (2004) (186)
- Treatment of primary Sjögren syndrome with rituximab: a randomized trial. (2014) (185)
- Treatment of Primary Sjgren Syndrome With Rituximab (2014) (184)
- The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. (2007) (181)
- Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production (2006) (179)
- B cells in the pathogenesis of primary Sjögren syndrome (2018) (178)
- Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. (2012) (177)
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). (2018) (173)
- Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. (2015) (170)
- Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome (2016) (169)
- In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. (2003) (165)
- Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. (2011) (164)
- Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. (2013) (163)
- RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. (2002) (160)
- Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome (2004) (159)
- COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study (2021) (158)
- Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjögren's syndrome. (1991) (153)
- Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. (2016) (152)
- Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis (2013) (152)
- Usefulness of 2‐[18F]‐fluoro‐2‐deoxy‐d‐glucose–Positron Emission Tomography/Computed Tomography for Staging and Evaluation of Treatment Response in IgG4‐Related Disease: A Retrospective Multicenter Study (2014) (152)
- Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome (2016) (151)
- Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers (2016) (150)
- Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort (2013) (148)
- Autoimmune and inflammatory disorders and risk of malignant lymphomas – an update (2008) (148)
- B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. (2011) (147)
- Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists (2006) (146)
- Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren’s syndrome (2006) (143)
- French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers (2003) (143)
- The Spectrum of Type I Cryoglobulinemia Vasculitis (2013) (143)
- Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR‐ and type‐I IFN‐dependent and ‐independent pathways (2008) (143)
- RANK (receptor activator of nuclear factor‐κB) and RANKL expression in multiple myeloma (2002) (141)
- CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. (2005) (137)
- Systemic and organ-specific immune-related manifestations of COVID-19 (2021) (137)
- Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma (1999) (135)
- Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. (2017) (135)
- Renal involvement in primary Sjögren syndrome (2016) (135)
- Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. (2006) (134)
- Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. (1997) (133)
- Granulocytic sarcoma (chloroma): imaging findings in adults and children. (2002) (131)
- Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. (2006) (131)
- High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. (1993) (131)
- Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA) (2014) (129)
- Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. (2014) (128)
- Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene (2014) (128)
- Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. (2008) (127)
- Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. (2013) (126)
- Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium (2016) (125)
- Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry (2012) (125)
- The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound (2012) (124)
- Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. (2016) (122)
- Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) (2015) (120)
- Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome. (2014) (118)
- Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations (2016) (116)
- Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. (2009) (115)
- How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). (2018) (115)
- Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. (2009) (114)
- A randomised clinical trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM (1997) (114)
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors (2020) (112)
- Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. (2015) (111)
- Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. (2007) (110)
- Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry (2011) (108)
- Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus (2015) (108)
- Myositis as a manifestation of SARS-CoV-2 (2020) (108)
- The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome. (2009) (108)
- NCR3/NKp30 Contributes to Pathogenesis in Primary Sjögren’s Syndrome (2013) (107)
- Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells (2001) (107)
- TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits (2015) (105)
- Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy (2007) (104)
- Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. (2005) (103)
- Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry (2010) (102)
- Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance (2015) (102)
- Brief Report: Association of Rheumatoid Factor and Anti–Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan‐European Registry Analysis (2016) (102)
- Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis (2012) (101)
- Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features. (2006) (100)
- Epidemiology of Primary Sjögren's Syndrome in a French Multiracial/Multiethnic Area (2014) (100)
- Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. (2013) (99)
- X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome (2015) (96)
- Pathogenesis of Sjögren's syndrome and therapeutic consequences (2010) (96)
- Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. (2017) (96)
- Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. (2006) (93)
- Classification criteria for Sjögren's syndrome: we actually need to definitively resolve the long debate on the issue (2012) (93)
- Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis. (1999) (93)
- Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. (2011) (92)
- B‐cell Activating Factor of the Tumour Necrosis Factor Family Expression in Blood Monocytes and T Cells from Patients with Primary Sjögren’s Syndrome (2008) (91)
- Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren’s syndrome and systemic lupus erythematosus (2006) (91)
- Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy (2012) (88)
- Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort (2016) (88)
- Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie. (1998) (86)
- Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. (2021) (85)
- Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the Autoimmunity and Rituximab Registry (2012) (83)
- Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab (2012) (83)
- Detection of human T lymphotropic virus type I tax gene in salivary gland epithelium from two patients with Sjögren's syndrome. (1993) (82)
- Outcome measures for primary Sjögren's syndrome: a comprehensive review. (2014) (82)
- Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort (2009) (82)
- A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis (2007) (81)
- Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort (2012) (81)
- Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome (2005) (81)
- Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials (2013) (81)
- Severe Health‐Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient‐Reported Outcomes: Data From a Large Therapeutic Trial (2017) (80)
- Tumour necrosis factor α −308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis (2009) (80)
- Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome (2015) (79)
- Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry (2021) (79)
- Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (2010) (77)
- Image‐guided core‐needle biopsy in patients with suspected or recurrent lymphomas (2000) (77)
- Sjogren's syndrome is associated with and not secondary to systemic sclerosis. (2006) (76)
- Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. (2013) (75)
- European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient‐Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients (2013) (74)
- Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis (2016) (74)
- Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study (2010) (74)
- Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study (2019) (73)
- Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium (2015) (73)
- Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study (2016) (73)
- Functional study of TNF-α promoter polymorphisms: literature review and meta-analysis. (2011) (72)
- CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome (2015) (72)
- Non HCV-related infectious cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey and systematic review of the literature. (2015) (71)
- Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial (2013) (71)
- Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. (1999) (71)
- Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. (2006) (71)
- Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren’s syndrome (2017) (71)
- Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjögren's syndrome. (2004) (70)
- Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. (2007) (70)
- Update of French society for rheumatology recommendations for managing rheumatoid arthritis. (2019) (69)
- Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. (2015) (69)
- TNF alpha antagonist therapy and safety monitoring. (2011) (68)
- Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study (2009) (67)
- The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. (2014) (67)
- Hepatitis C virus and Sjögren's syndrome. (1993) (66)
- Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. (2007) (66)
- Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study (2011) (66)
- Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project (2017) (65)
- Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry (2015) (64)
- Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. (2016) (63)
- Characteristics and survival of 26 patients with paraneoplastic arthritis (2007) (62)
- Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. (2015) (62)
- Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials (2019) (61)
- The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. (2005) (61)
- Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials (2019) (61)
- Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis (2007) (61)
- Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome. (2007) (60)
- Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies (2016) (60)
- Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. (1994) (60)
- Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. (2011) (60)
- Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme (2020) (59)
- Abatacept therapy and safety management. (2009) (59)
- Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A French Nationwide Study of Ninety‐Two Patients (2015) (59)
- New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. (2015) (58)
- Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy. (2007) (58)
- Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort (2015) (57)
- Presence of microchimerism in labial salivary glands in systemic sclerosis but not in Sjögren's syndrome. (2002) (57)
- Tocilizumab: therapy and safety management. (2010) (56)
- A randomised double blind trial versus placebo does not confirm the benefit of α-interferon in polyneuropathy associated with monoclonal IgM (2000) (55)
- Prevalence of hepatitis G virus RNA in French blood donors and recipients (1997) (55)
- Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. (2006) (55)
- Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy (2017) (55)
- A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome (2016) (53)
- Use of Whole‐Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open‐Label Trial (2014) (53)
- Rituximab (MabThera) therapy and safety management. Clinical tool guide. (2008) (53)
- 2021 DORIS definition of remission in SLE: final recommendations from an international task force (2021) (53)
- Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. (2008) (52)
- Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons (2017) (52)
- Outcome measures for primary Sjögren's syndrome. (2012) (52)
- Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. (2013) (52)
- Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). (2019) (52)
- STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling (2010) (51)
- Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors (2017) (50)
- The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression (2004) (50)
- Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. (2006) (50)
- [Pathophysiology of Sjögren's syndrome]. (2003) (50)
- EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update (2022) (50)
- Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity (2008) (49)
- Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). (2005) (49)
- Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. (2005) (49)
- CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. (2013) (49)
- Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE (2017) (49)
- Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma. (2019) (49)
- Association of Anti–Porphyromonas gingivalis Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis (2015) (49)
- Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. (2016) (48)
- Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort (2013) (48)
- Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey (2012) (48)
- Off-label use of rituximab for systemic lupus erythematosus in Europe (2016) (47)
- Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. (2012) (47)
- Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort (2016) (46)
- Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019 (2019) (46)
- Detection of the tax gene of HTLV-I in labial salivary glands from patients with Sjögren's syndrome and other diseases of the oral cavity. (2000) (46)
- No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome (2006) (46)
- No evidence for association between 1858 C/T single-nucleotide polymorphism of PTPN22 gene and primary Sjögren's syndrome (2005) (46)
- Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study (2015) (46)
- Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. (2019) (44)
- Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma (2015) (44)
- Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. (2005) (44)
- Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome (2015) (44)
- Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. (2014) (43)
- Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. (2013) (42)
- Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate. (1998) (42)
- Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial (2014) (42)
- Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction (1998) (42)
- Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial (2019) (41)
- Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy (1995) (41)
- The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. (2017) (41)
- Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry. (2012) (41)
- Safety of Surgery After Rituximab Therapy in 133 Patients With Rheumatoid Arthritis: Data From the AutoImmunity and Rituximab Registry (2013) (41)
- Anti-carbamylated protein antibodies presence in early arthritis with a poorer clinical and radiological outcome: data from the French ESPOIR cohort (2017) (41)
- B‐cell‐activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA‐activated protein kinase activation (2009) (40)
- Severe chronic bronchiolitis as the presenting feature of primary Sjögren's syndrome. (2011) (40)
- The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries (2015) (40)
- Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry (2015) (39)
- TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. (2006) (39)
- Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. (2019) (39)
- Detection of human herpesvirus-8 DNA in bone marrow biopsies from patients with multiple myeloma and Waldenström's macroglobulinemia. (1998) (39)
- Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort (2021) (39)
- Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials (2019) (39)
- Bone densitometry in patients with multiple myeloma. (1992) (38)
- First‐Year Radiographic Progression as a Predictor of Further Progression in Early Arthritis: Results of a Large National French Cohort (2013) (38)
- Passive smoking in childhood increases the risk of developing rheumatoid arthritis. (2018) (38)
- Salivary gland epithelial cells from patients with Sjögren’s syndrome induce B-lymphocyte survival and activation (2020) (38)
- Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. (2006) (38)
- Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry (2010) (38)
- Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. (2016) (38)
- Rituximab Impairs B Cell Response But Not T Cell Response to COVID‐19 Vaccine in Autoimmune Diseases (2021) (38)
- Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome (2018) (38)
- Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. (2019) (37)
- Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome (2019) (37)
- Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for Primary Sjögren’s syndrome (2020) (37)
- Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Differentially Modulated by Different TNF Inhibitors (2019) (37)
- Induction of B Cell-Activating Factor by Viral Infection Is a General Phenomenon, but the Types of Viruses and Mechanisms Depend on Cell Type (2010) (37)
- Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. (2005) (37)
- Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial (2020) (36)
- Lack of efficacy of rituximab in Felty’s syndrome (2005) (36)
- ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome? (2015) (36)
- Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA) (2017) (36)
- Current and future therapies for primary Sjögren syndrome (2021) (35)
- Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1 (2018) (35)
- Association of the Presence of Anti–Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome (2017) (34)
- Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry (2014) (34)
- Rituximab: a new therapeutic alternative in rheumatoid arthritis. (2008) (34)
- Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study (2017) (34)
- Low back pain in rural Tibet (2003) (34)
- Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study (2018) (34)
- Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. (2006) (34)
- The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy (2017) (33)
- Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial (2021) (33)
- Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions? (2018) (33)
- Combination of the Schirmer I and phenol red thread tests as a rescue strategy for diagnosis of ocular dryness associated with Sjögren's syndrome. (2011) (33)
- Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone. (1991) (33)
- Hepatitis C Virus in Saliva (1995) (33)
- Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease (2016) (32)
- Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities (2020) (32)
- Immunogenicity of tocilizumab in patients with rheumatoid arthritis. (2017) (32)
- EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19 (2021) (32)
- Sjögren’s syndrome: state of the art on clinical practice guidelines (2018) (31)
- STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling (2010) (31)
- Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection (2018) (31)
- Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program (2018) (30)
- Low-grade MALT lymphoma mimicking Waldenström's macroglobulinemia (1999) (30)
- Role of the IL‐12/IL‐35 balance in patients with Sjögren syndrome (2017) (30)
- Failure to confirm coxsackievirus infection in primary Sjögren's syndrome. (2006) (30)
- Rheumatoid arthritis of the hand: monitoring with a simplified MR imaging scoring method--preliminary assessment. (2010) (29)
- Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance (2022) (29)
- Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies (2009) (29)
- Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data (2017) (29)
- Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. (2018) (29)
- Upregulation of Membrane‐Bound CD40L on CD4+ T cells in Women with Primary Sjögren's Syndrome (2014) (29)
- A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. (1997) (28)
- IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. (2009) (28)
- Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease? (2019) (28)
- A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis (2017) (27)
- Structural analysis of human antibodies to proteinase 3 from patients with Wegener granulomatosis. (1997) (27)
- Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis (2016) (27)
- Recovery from pulmonary hypertension with steroid therapy in a patient with Sjögren's syndrome and polymyositis. (1994) (27)
- Methylation profile of the promoter region of IRF5 in primary Sjögren's syndrome. (2012) (27)
- Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study (2016) (27)
- Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome (2017) (27)
- International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. (2017) (27)
- Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. (2017) (27)
- [Sjögren's syndrome and virus]. (1994) (27)
- Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study (2014) (26)
- Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. (2019) (26)
- Paradoxical anti-TNF-associated TB worsening: Frequency and factors associated with IRIS. (2016) (26)
- TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer (2017) (26)
- The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. (2016) (26)
- Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018 (2019) (26)
- Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement (2005) (26)
- Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider (2021) (26)
- The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. (2020) (26)
- Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter Cohort (2012) (26)
- Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort (2015) (25)
- THU0174 Analysis of Non-melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Programme (2015) (25)
- Surgical endoscopic techniques in the diagnosis and follow‐up of patients with lymphoma (1998) (25)
- The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET (2021) (25)
- Idiopathic interstitial lung disease with anti-SSA antibody. (2011) (25)
- European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance (2021) (25)
- Use of Biologics in Sjögren's Syndrome. (2016) (25)
- Effectiveness of platelet transfusions after plasma exchange in adult thrombotic thrombocytopenic purpura: A report of two cases (2001) (24)
- Medical treatment of synovial cysts of the zygapophyseal joints: four cases with long-term followup. (1989) (24)
- Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial (2021) (24)
- Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge (2013) (24)
- The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. (2020) (24)
- Management of rheumatic complications of ICI therapy: a rheumatology viewpoint (2019) (24)
- OP0020 Validation of new systemic lupus erythematosus classification criteria (2018) (24)
- Mediterranean Diet and Risk of Rheumatoid Arthritis: Findings From the French E3N‐EPIC Cohort Study (2020) (24)
- Abatacept therapy and safety management. (2012) (23)
- Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. (2014) (23)
- Anti‐Porphyromonas gingivalis antibodies titres are associated with non‐smoking status in early rheumatoid arthritis: Results from the ESPOIR cohort (2015) (23)
- French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides) (2020) (23)
- Antibodies to HTLV-I in Sjögren's syndrome (1995) (23)
- SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases (2021) (23)
- Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry (2021) (22)
- Cytomegalovirus Colitis and Hypo-IgG After Rituximab Therapy for Rheumatoid Arthritis (2011) (22)
- Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome? (2015) (22)
- A new MHC‐linked susceptibility locus for primary Sjögren's syndrome: MICA (2017) (22)
- Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39 (2019) (22)
- Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors (2012) (22)
- Neurolymphomatosis in Waldenström's macroglobulinaemia (1999) (22)
- Tumoral joint involvement in multiple myeloma and Waldenström's macroglobulinemia--report of 4 cases. (1996) (21)
- Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study (2017) (21)
- Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort (2014) (21)
- CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjögren syndrome (2007) (21)
- Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry) (2012) (21)
- Therapeutic potential for B-cell modulation in Sjögren's syndrome. (2008) (21)
- Malignancy and the Risks of Biologic Therapies: Current Status. (2017) (21)
- Genome-Wide Association Study and Gene Expression Analysis Identifies CD 84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis (2013) (21)
- Effect of response format for clinical vignettes on reporting quality of physician practice (2009) (21)
- Iron Supplementation–Induced Phosphaturic Osteomalacia: FGF23 is the Culprit (2018) (21)
- New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS (2019) (21)
- Iliac artery dissection in α1-antitrypsin deficiency (1994) (20)
- Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey. (2009) (20)
- A Randomized Comparison of Dexamethasone + Thalidomide (Dex/Thal) vs Dex + Placebo (Dex/P) in Patients (pts) with Relapsing Multiple Myeloma (MM). (2006) (20)
- Usefulness of 18F‐Labeled Fluorodeoxyglucose–Positron Emission Tomography for the Diagnosis of Lymphoma in Primary Sjögren's Syndrome (2019) (20)
- Intensive Therapy in AL Amyloidosis and Light-Chain Deposition Disease (1995) (20)
- 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 (2021) (20)
- Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium (2020) (20)
- Characterization of a human monoclonal autoantibody directed to cardiolipin/β2 glycoprotein I produced by chronic lymphocytic leukaemia B cells (1993) (20)
- Evaluation of Bone Mineral Density and Fat‐Lean Distribution in Patients With Multiple Myeloma in Sustained Remission (2003) (20)
- THU0392 Efficacy and Safety of Belimumab Given for 12 Months in Primary sjögren's Syndrome: The Beliss Open-Label Phase II Study (2015) (19)
- LB0002 COVID-19 VACCINE SAFETY IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASE (2021) (19)
- RANK and RANKL expression in giant-cell tumour of bone. (2010) (19)
- The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. (2017) (19)
- Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts (2015) (19)
- Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey. (2014) (19)
- Current and potential treatments for primary Sjögren's syndrome. (2002) (19)
- A multi-parameter response prediction model for rituximab in rheumatoid arthritis. (2017) (19)
- Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls (2021) (19)
- Specific cardiomyopathy in lupus patients: report of three cases. (2004) (19)
- To immunosuppress: whom, when and how? That is the question with COVID-19 (2020) (19)
- Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide. (2002) (19)
- Emerging biological therapies in rheumatoid arthritis. (2004) (19)
- Iliac artery dissection in alpha 1-antitrypsin deficiency. (1994) (18)
- Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. (2007) (18)
- OP0066 Targeting the Lowest Efficacious Dose for Rheumatoid Arthritis Patients in Remission: Clinical and Structural Impact of a Step-Down Strategy Trial Based on Progressive Spacing of TNF-Blocker Injections (Strass Trial) (2013) (18)
- A new defensive mechanism to prevent apoptosis in salivary ductal cells from patients with Sjögren's syndrome: over-expression of p53 and p21. (2002) (18)
- Nucleotidic sequence analysis of the variable domains of four human monoclonal IgM with an antibody activity to myelin‐associated glycoprotein (1993) (18)
- Determination of the affinity of monoclonal human IgM for myelin-associated glycoprotein and sulfated glucuronic paragloboside (1992) (18)
- Methotrexate and BAFF interaction prevents immunization against TNF inhibitors (2018) (18)
- Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept. (2014) (18)
- Monarthritis revealing non-Hodgkin's T cell lymphoma of the synovium. (1988) (18)
- Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. (2007) (17)
- Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020 (2020) (17)
- Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. (2019) (17)
- Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis (2018) (17)
- Improving accuracy of self-reported diagnoses of rheumatoid arthritis in the French prospective E3N-EPIC cohort: a validation study (2019) (17)
- Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease (2016) (17)
- Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjögren's syndrome. (1999) (17)
- High‐dose therapy and autologous blood stem cell transplantation in multiple myeloma: Preliminary results of a randomized trial involving 167 patients (1995) (17)
- Dry eyes and mouth syndrome or sicca, asthenia and polyalgia syndrome? (2003) (17)
- Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study (2019) (17)
- Lymphoma, rheumatoid arthritis, and TNFalpha antagonists. (2010) (16)
- Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial. (2017) (16)
- Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. (2021) (16)
- A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. (2020) (16)
- Potential Classification Criteria for Rheumatoid Arthritis After Two Years: Results From a French Multicenter Cohort (2013) (16)
- Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. (2007) (16)
- Anti-α-fodrin autoantibodies are not useful diagnostic markers of primary Sjögren’s syndrome (2005) (16)
- Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group (2022) (16)
- Monoclonal IgM from patients with peripheral demyelinating neuropathies cross‐react with bacterial polypeptides (1994) (15)
- Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry (2017) (15)
- Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. (2007) (15)
- Interleukin‐7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren’s Syndrome (2020) (15)
- Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry (2017) (15)
- Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits (2015) (15)
- Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement (2019) (14)
- THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY) (2019) (14)
- Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone (2020) (14)
- Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases (2017) (14)
- Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis (2016) (14)
- Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis (2017) (14)
- Is Inhibitor of differentiation 3 involved in human primary Sjögren's syndrome? (2008) (14)
- Hematological malignancies and the bone (myeloma excluded). (2000) (14)
- Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome (2019) (14)
- Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS. (2020) (13)
- Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus. (2006) (13)
- X chromosome dose and sex bias in autoimmune diseases: increased 47,XXX in systemic lupus erythematosus and Sjögren’s syndrome (BA4P.211) (2014) (13)
- The hepatitis C virus and systemic diseases. (1998) (13)
- Nucleotide sequence analysis of the VL and VH domains of five human IgM directed to lamin B. Evidence for an antigen-driven process in the generation of human autoantibodies to lamin B. (1993) (13)
- Role of good oral hygiene on clinical evolution of rheumatoid arthritis: a randomized study nested in the ESPOIR cohort. (2020) (13)
- Chronic diarrhoea and risk of rheumatoid arthritis: findings from the French E3N-EPIC Cohort Study. (2020) (13)
- OP0017 Lack of placental transfer of certolizumab pegol during pregnancy: results from crib, a prospective, postmarketing, multicenter, pharmacokinetic study (2017) (13)
- Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome (2022) (12)
- The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region (2015) (12)
- Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. (2021) (12)
- University of Groningen Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjogren's Syndrome Post Hoc Analyses From the EMBODY Trials (2018) (12)
- Use of an abdominal compression device for CT-guided biopsy of enlarged abdominal or pelvic lymph nodes. (1998) (12)
- OP0065 Tolerance and efficacy of rituximab in primary sjogren syndrome (TEARS): Results of a randomized controlled trial (2013) (12)
- THU0131 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical programme (2013) (11)
- [The phenol red thread first results for the assessment of the cut-off value in ocular sicca syndrome]. (2002) (11)
- Epidemiologic Subsets Drive a Differentiated Clinical and Immunological Presentation of Primary Sjogren Syndrome : Analysis of 9302 Patients from the Big Data International Sjogren Cohort (2017) (11)
- Granulocyte colony-stimulating factor therapy resulting in a flare of systemic lupus erythematosus: comment on the article by Yang and Hamilton. (2001) (11)
- Focal myositis with fasciitis and vasculitis revealing chronic lymphocytic leukaemia. (2005) (11)
- Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial (2017) (11)
- Treatment of multiple myeloma. (2003) (11)
- Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider (2021) (11)
- Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases. (2020) (10)
- Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial. (2017) (10)
- SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients (2020) (10)
- SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients (2020) (10)
- Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients. (2015) (10)
- A patient with chronic lymphoid leukemia and recurrent necrotic herpetic lymphadenitis. (1999) (10)
- Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). (2020) (10)
- Absence of HTLV-1tax in Sjögre's syndrome (1996) (10)
- New biological therapies in Sjögren's syndrome. (2015) (10)
- Trans-ancestry genome-wide association study identifies novel genetic mechanisms in rheumatoid arthritis (2021) (10)
- Rituximab‐Bendamustine (R‐Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS) (2019) (10)
- Brief Report: The Role of Rare Protein‐Coding Variants in Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis (2017) (10)
- How does BAFF activate B cells in patients with autoimmune diseases? (2012) (10)
- Anti-{alpha}-fodrin autoantibodies are not useful diagnostic markers of primary Sjögren's syndrome. (2005) (10)
- Evaluation of two strategies (initial methotrexate monotherapy versus its combination with adalimumab) in management of early active rheumatoid arthritis during the first year of evolution: Data from 3 the Guepard trial (2008) (9)
- OP0217 Defining Disease Activity Sates and Minimal Clinically Important Improvement (MCII) with the EULAR Primary SjÖGren's Syndrome Disease Activity Index (ESSDAI) (2014) (9)
- OP0135 SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY (2021) (9)
- Genetic contribution of DKK-1 polymorphisms to RA structural severity and DKK-1 level of expression (2015) (9)
- A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease (2022) (9)
- Small fiber neuropathy in Sjögren syndrome: Comparison with other small fiber neuropathies (2020) (9)
- FRI0322 Positivity for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide is Associated with A Better Drug Retention of Abatacept: Data from A Paneuropean Analysis of RA Registries (2014) (9)
- Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence (2020) (9)
- Tolerance and efficacy of rituximab in primary Sjögren syndrome (TEARS): results of the randomized controlled trial. (2012) (9)
- Rifampicin-induced pure red cell aplasia. (1989) (9)
- SAT0165 Improvements in Patient-Reported Outcomes and Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients: Results from the C-Early Randomized, Double-Blind, Controlled Phase (2015) (9)
- JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis (2019) (9)
- Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program (2018) (9)
- Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group (2022) (9)
- Cisplatin and hyponatremia. (1988) (9)
- [Sjögren syndrome in Obstetric and Gynecology: literature review]. (2006) (9)
- The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases. (2004) (8)
- Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. (2020) (8)
- Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine (2021) (8)
- Interleukin 10: a new therapeutic target in systemic lupus erythematosus? (2001) (8)
- Rethinking Primary Sjogren's Syndrome: Stratification By Clinical Phenotypes to Improve Understanding of Disease Pathogenesis, Trial Design, Clinical Management and Prospective Health Gains? (2016) (8)
- Hepatitis C virus, arthritides, and arthromyalgia. (2003) (8)
- Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses (2022) (8)
- Clinical relevance of ROR&ggr; positive and negative subsets of CD161+CD4+ T cells in primary Sjögren’s syndrome (2017) (8)
- Methotrexate treatment and mortality in rheumatoid arthritis. Authors' reply (2002) (8)
- Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients (2019) (8)
- Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis (2022) (8)
- Retroperitoneal fibrosis secondary to spondylodiscitis after infection with Prevotella. (2005) (8)
- FRI0323 Prospective Follow-Up of Tocilizumab Treatment in 1503 Patients with Refractory Rheumatoid Arthritis: Tolerance Data at 1 Year from the French Registry Regate (Registry – Roactemra) (2013) (7)
- Severe deafness associated with Crohn's disease and spondylarthropathy: successful treatment with anti-TNF. (2013) (7)
- Immune interventions in COVID-19: a matter of time? (2021) (7)
- Tumour necrosis factor receptor 2 (TNFRSF1B) association study in Sjögren’s syndrome (2007) (7)
- Association between-871 C > T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients (2013) (7)
- Normal salivary gland ultrasonography could rule out the diagnosis of Sjögren’s syndrome in anti-SSA-negative patients with sicca syndrome (2021) (7)
- Both Systemic and Intra-articular Immunization with Citrullinated Peptides Are Needed to Induce Arthritis in the Macaque (2017) (7)
- Risk of Diverticulitis and Gastrointestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab or Abatacept. (2021) (7)
- Characterization of Phenotypes and Functional Activities of Leukocytes From Rheumatoid Arthritis Patients by Mass Cytometry (2019) (7)
- Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sjögren syndrome (2021) (7)
- Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider (2021) (7)
- Denosumab in patients with bone metastases from prostate, breast, and other cancers and elevated urinary N-telopeptide (uNTx) during intravenous bisphosphonate (IV BP) therapy: Final results of a randomized, phase II study (2008) (7)
- Absence of cytomegalovirus and Epstein-Barr virus expression in labial salivary glands of patients with chronic graft-versus-host disease. (1996) (7)
- Pulmonary Hodgkin's disease in HIV-infected patient. Diagnosis by bronchoalveolar lavage. (1992) (7)
- Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis (2018) (7)
- THU0180 Impact of Progressive Spacing of TNF-Blocker Injections on Signs and Symptoms of Rheumatoid Arthritis Patients in DAS28 Remission: The Strass Randomized Controled Trial (2013) (6)
- [Polyclonal B lymphocytosis and hyper-IgM: immunodeficiency and/or benign lymphoid proliferation associated with tobacco?]. (2000) (6)
- Female hormonal exposures and risk of rheumatoid arthritis in the French E3N-EPIC cohort study. (2021) (6)
- Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients (2018) (6)
- Features of polymyalgia rheumatica–like syndrome after immune checkpoint inhibitor therapy (2020) (6)
- FRI0313 Body Mass Does not Affect Clinical Outcomes of Therapy with Abatacept in Rheumatoid Arthritis (RA) Patients. A Pan-European Analysis of RA Registries (2014) (6)
- Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis (2021) (6)
- 099. Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers (2015) (6)
- Efficacy of Belimumab On Non-Malignant Parotid Swelling and SystemicManifestations of Sjo¨gren’s Syndrome: Results of the Beliss Study. (2012) (6)
- OP0020 Identification of Multiple Sjögren’s Syndrome Susceptibility Loci (2013) (6)
- FRI0303 Validation of eular primary sjögren’s syndrome disease activity and patient indexes (2012) (6)
- SP0190 2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJöGREN”S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES (2019) (6)
- Corrigendum: Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements [Rheumatology, 54, (2015) (2230-2238)] DOI: 10.1093/rheumatology/kev200 (2017) (6)
- [Treatment of oral dryness in Sjögren's syndrome]. (2004) (6)
- OP0287 IMMUNOMODULATORY THERAPIES FOR SEVERE FORMS OF COVID-19: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER (2021) (6)
- Sensorimotor polyneuropathy and monoclonal IgM: A review of clinical and immunological features (1992) (6)
- Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. (2021) (6)
- Orbital Myositis and Primary Sjögren Syndrome (2015) (6)
- Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. (2021) (6)
- Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications (2020) (6)
- Differential levels of IFNα subtypes in autoimmunity and viral infection (2021) (5)
- AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (PSS) (2019) (5)
- Characterization and outcomes of 414 patients with primary SS who developed hematological malignancies. (2022) (5)
- Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis (2021) (5)
- B-Cell-Targeted Therapies in Sjögren’s Syndrome (2011) (5)
- Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey (2013) (5)
- Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study. (2013) (5)
- Primary Sjögren's syndrome: time for prospective cohorts. (2012) (5)
- The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. (2022) (5)
- Hepatitis C virus and lymphomagenesis: Another piece of evidence (2002) (5)
- [Multicentric reticulohistiocytosis. A case with unusual clinical, radiologic and ultrastructural aspects]. (1987) (5)
- AB0361 ASCORE, A 2-YEAR, OBSERVATIONAL, PROSPECTIVE MULTICENTRE STUDY OF SUBCUTANEOUS ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE: 1-YEAR INTERIM ANALYSIS (2019) (5)
- Seasonal effect on fatigue, pain and dryness in primary Sjögren’s syndrome (2020) (5)
- Primary Sjögren's Syndrome. (2018) (5)
- TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis. (2021) (5)
- OP0284 Impact of a Nurse Led Program of Patient Self-Assessment of Disease Activity on the Management of Rheumatoid Arthritis: Results of a Prospective, Multicentre, Randomized, Controlled Trial (Comedra) (2013) (5)
- Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells (2022) (5)
- Hypocalcaemia due to parathyroid metastases. (1993) (5)
- SAT0164 The First Study of Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients Led to Sustained Clinical Response and Inhibition of Radiographic Progression at 52 Weeks: The C-Early Randomized, Double-Blind, Controlled Phase 3 Study (2015) (5)
- A Genome-Wide Association Study Establishes Muliple Susceptibility Loci for Sjogren's Syndrome (2012) (5)
- OP0035 Tolerance of Rituximab, Abatacept and Tocilizumab in Common Practice: Analysis of the 3 Registries of the French Society of Rheumatology (Air, Ora and Regate) (2015) (4)
- Small hepatic vein involvement in IgG multiple myeloma: a very unusual pattern of liver infiltration (2006) (4)
- Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus (2022) (4)
- Morphologic heterogeneity and plasmablastic transformation in advanced plasmacytic/plasmablastic myeloma: a study of 35 serial bone marrow biopsies in 9 patients. (1989) (4)
- OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN’S SYNDROME (2020) (4)
- Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor? (2016) (4)
- THU0649 PHENOTYPIC CLUSTERS OF RHEUMATIC/SYSTEMIC IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES (IMMUNOCANCER INTERNATIONAL REGISTRY) (2019) (4)
- THU0066 Do Predictors of IV Abatacept Retention Depend on The Line of Rheumatoid Arthritis Treatment: 12-Month Interim Analysis of The Observational, Prospective Action Study (2016) (4)
- Concomitant fibromyalgia in primary Sjögren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FiRST questionnaire and physician's opinion. (2021) (4)
- Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. (2019) (4)
- Sex Bias In Autoimmune Diseases : Increased Risk Of 47,XXX In Systemic Lupus Erythematosus (SLE) and Sjogren's Syndrome (SS) Supports The Gene Dose Hypothesis (2013) (4)
- Perioperative Management of Patients with Rheumatoid Arthritis Treated with TNF-a Blocking Agents (2007) (4)
- Rectus femoris sheath: a new localization of hip synovial cyst. (1989) (4)
- Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). (2021) (4)
- IgG4 multiorgan lymphoproliferative syndrome as a differential diagnosis of primary Sjögren's syndrome in men? (2011) (4)
- [Sjögren's syndrome. Relation to viral infections]. (1993) (4)
- [Anti-cytokines in the treatment of inflammation]. (2003) (4)
- Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications (2018) (4)
- Fish Consumption and Risk of Rheumatoid Arthritis: Findings from the E3N Cohort Study (2022) (4)
- Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. (2020) (4)
- Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis. (2016) (4)
- Efficacy and safety of adalimumab (Humira (R)) in European clinical practice: The ReAct trial (2005) (4)
- Cost-effectiveness of rituximab strategies in rheumatoid arthritis (2017) (4)
- [Gougerot-Sjögren syndrome. Risk of lymphoma]. (1999) (4)
- THU0204 The Positive Effect of Stringent Criteria for Purified Protein Derivation (PPD) Skin Test on Patients Treated with Certolizumab Pegol (2013) (3)
- [False hyperphosphoremia in multiple myeloma]. (1989) (3)
- Author Correction: Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells (2022) (3)
- Triple X Syndrome (47,XXX) Increases the Risk and Accelerates the Onset of Systemic Lupus Erythematosus and Sjogren's Syndrome: Support for a Gene-Dose Effect From the X Chromosome (2011) (3)
- THU0087 One single infusion of rituximab 1g might be sufficient in the long-term management of rheumatoid arthritis patients responding to a first cycle of rituximab (2 × 1g): Results of a 2-year multi-center randomized controlled trial (2013) (3)
- Infl uence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy (2012) (3)
- Passive smoking in childhood and adulthood and risk of rheumatoid arthritis in women: results from the French E3N cohort study (2022) (3)
- THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study (2013) (3)
- Improvements in Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study. (2015) (3)
- OP0089 Big Data Sjögren Project (Eular-SS Task Force International Network): Characterization at Diagnosis of 5027 Patients with Primary Sjögren Syndrome (2015) (3)
- OP0234 Impact of a Nurse Led Program on the Management of Comorbidities in Rheumatoid Arthritis (RA). Results of a Prospective, Multicentre, Randomized, Controlled Trial (Comedra) (2013) (3)
- Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to do. (2017) (3)
- OP0022 RISK OF DIVERTICULITIS AND GASTRO-INTESTINAL PERFORATION IN RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB COMPARED TO RITUXIMAB AND ABATACEPT: A PROSPECTIVE PROPENSITY-MATCHED COHORT STUDY (2020) (3)
- FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra) (2013) (3)
- OP0253 Passive smoking in childhood and history of chronic diarrhea increases the risk of developing rheumatoid arthritis (RA) (2017) (3)
- OP0114 Inefficacy of Hydroxychoroquine in Primary Sjögren’s Syndrome: Results at 12 Months of the Randomized Placebo-Controlled Trial of Plaquenil in Primary Sjögren’s Syndrome (2013) (3)
- OP0165 EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY (2019) (3)
- Restoration of Default Blood Monocyte-Derived Macrophage Polarization With Adalimumab But Not Etanercept in Rheumatoid Arthritis (2022) (3)
- OP0124 RISK OF MALIGNANCIES ACROSS BIOLOGIC CLASSES IN RHEUMATOID ARTHRITIS: ANALYSIS OF A NATIONAL CLAIM DATABASE (2020) (3)
- O471 A risk of tuberculosis persists in patients treated with anti TNF-a antagonist therapy despite prophylactic guidelines: identification of main risk factors (2007) (3)
- Primary Sjögren's Syndrome Prevalence: What if Sjögren was Right After All? Comment on the Article by Maciel et al (2018) (3)
- Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy. (2018) (3)
- First Results of a European Registries Collaborative Project to Compare the Spectrum of Lymphomas Between Different Exposure Groups in Rheumatoid Arthritis (2014) (3)
- Lymphoma complicating rheumatoid arthritis: results from a French case–control study (2021) (3)
- [Primary Sjögren's syndrome complicated by gastric lymphoma. Study of Epstein-Barr viral DNA in the tumor]. (1989) (3)
- Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren’s Syndrome (2021) (3)
- Role of the IL-12 / IL-35 balance in Sjögren ’ s syndrome 1 2 (2017) (3)
- Low dose interferon-alpha to treat Behçet's disease. (2007) (3)
- Regulatory T Cells Increase After rh-MOG Stimulation in Non-Relapsing but Decrease in Relapsing MOG Antibody-Associated Disease at Onset in Children (2021) (3)
- [Bone marrow transplantation in the treatment of autoimmune diseases. ISAMAIR Group]. (1999) (3)
- Efficacy and safety of convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized clinical trial (2022) (3)
- Successful treatment of agranulocytosis and sepsis with granulocyte colony stimulating factor in a case of Felty's syndrome. (1995) (3)
- SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry (2022) (3)
- Valine 11 and phenylalanine 13 have a greater impact on the T-cell response to citrullinated peptides than the 70–74 shared epitope of the DRB1 molecule in macaques (2019) (3)
- FRI0421 Development of Clinessdai Score (Clinical Eular Sjögren's Syndrome Disease Activity Index) Without Biological Domain: A Tool For Biological Studies (2015) (3)
- AB0462 The Lack of Antidrug Antibodies Among Patients Treated with Tocilizumab: A Clue to Good Efficacy Profiles When Used as Monotherapy? (2015) (3)
- THU0147 Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies across the Rheumatoid Arthritis Clinical Programme (2014) (3)
- A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome (2022) (3)
- THU0151 Effects of Tnfα-Blockers Tapering on Occurrence of Patient-Perceived Flares in Rheumatoid Arthritis: A Subanalysis of Strass (2014) (3)
- IgG4-related disease associated with renal microaneurysms and polycythaemia. (2016) (3)
- Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes (2019) (2)
- Identification of driver genes for severe forms of COVID-19 in a deeply phenotyped young patient cohort (2021) (2)
- OP0047 GENOME-WIDE ASSOCIATION STUDY OF SJÖGREN’S SYNDROME IDENTIFIES TEN NEW RISK LOCI (2020) (2)
- Flare of a mixed cryoglobulinaemic vasculitis after obinutuzumab infusion. (2021) (2)
- OP0154 Integrated Safety Analysis of Tofacitinib in RA Clinical Trials with A Cumulative Exposure of 12,664 Patient-Years (2014) (2)
- A High-Density Genome-Wide Association Study by the Sjogren's Genetics Network Identifies Five Novel Susceptibility Loci for Primary Sjogren's Syndrome and Confirms Association with MHC, IRF5, and BLK (2011) (2)
- Reply (2017) (2)
- OP0066 Efficacy of rituximab in systemic manifestations of patients with primary sjÖgren’s syndrome: Results from the air registry (2013) (2)
- [Bone and joints in inflammatory bowel disease]. (2004) (2)
- P110 TOFACITINIB is associated with an impaired function of NK cells and a defective immunosurveillance against B-cell lymphomas (2018) (2)
- Alcohol is not the missing link between Porphyromonas gingivalis-related periodontitis and radiological progression in early rheumatoid arthritis (2019) (2)
- Association between beverage consumption and risk of rheumatoid arthritis: a prospective study from the French E3N Cohort. (2022) (2)
- Phenotypic switch from non-active primary Sjögren's syndrome to severe systemic Lupus erythematosus after COVID-19 infection in an elderly man (2021) (2)
- Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study. (2015) (2)
- FRI0419 Big Data Sjogren Project (Eular-SS Task Force International Network): Systemic Involvement at Diagnosis Evaluated by the Essdai in 3314 Patients with Primary Sjögren Syndrome (2015) (2)
- OP0113 Modification of Salivary Gland Lymphocyte Pattern after Belimumab in Primary Sjogren’s Syndrome: Results of the Beliss Study (2013) (2)
- SAT0057 INCREASED MICRORNA-155 IS ASSOCIATED WITH A SPECIFIC DEFECT OF ANTI-INFLAMMATORY M2 MACROPHAGES POLARIZATION BOTH IN HUMAN RHEUMATOID ARTHRITIS AND IN COLLAGEN-INDUCED-ARTHRITIS MICE (2019) (2)
- POS0062 A RISK SCORE TO DETECT SUBCLINICAL RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (2022) (2)
- PMS82 – Clinical Responses and Improvements in Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol (2016) (2)
- EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy (2019) (2)
- OP0004 Rheumatoid arthritis occuring after immune checkpoint inhibitors (2017) (2)
- AB0516 An open-label randomized controlled study to evaluate the efficacy of etanercept (ETN) versus rituximab (RTX), in patients with active rheumatoid arthritis previously treated with RTX and TNF blockers (2013) (2)
- THU0282 EPIDEMIOLOGY OF CUTANEOUS INVOLVEMENT IN SJÖGREN’S SYNDROME: DATA FROM THREE FRENCH POPULATIONS OF PSS (TEARS, ASSESS, DIAPSS) (2020) (2)
- THU0225 Role of the IL-12/IL-35 balance in SJÖGREN'S syndrome (2017) (2)
- Use of 18F FDG PET-CT to discriminate polymyalgia rheumatica and atypical spondylarthritis in clinical practice. (2021) (2)
- CD4+ T-cell DNA methylation changes during pregnancy significantly correlate with disease-associated methylation changes in autoimmune diseases (2021) (2)
- Is miR200b-5p a new predictor of lymphoma or associated with lymphocytes infiltrate within salivary glands? (2018) (2)
- Perioperative management of patients with rheumatoid arthritis treated with TNF-alpha blocking agents. (2007) (2)
- Klinefelter's Syndrome (47,XXY) Among Men with Sjogren's Syndrome (2015) (2)
- FRI0245 Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2-year results from the real-world action study (2017) (2)
- Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic (2016) (2)
- OP0040 Integration of salivary-gland ultrasonography in classification criteria for primary sjÖgren's syndrome: an international vignette-based study (2017) (2)
- Correction to: French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides) (2021) (2)
- Denosumab in active Charcot neuro-osteorthropathy of the foot. (2021) (2)
- Monoclonal gammopathy of clinical significance: in vivo demonstration of the anti-thrombotic effect of an acquired anti-thrombin antibody (2020) (2)
- Interferon signature in systemic autoimmune diseases: what does it mean? (2022) (2)
- Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index (2021) (2)
- Cervical syphilitic spondylodiscitis associated with neurosyphilis. (2011) (2)
- OP0101 Bisphosphonates during Pregnancy: A Prospective Study (2016) (2)
- Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database (2022) (2)
- Modification of the Classification Criteria for Primary Sjogren Syndrome: An International Vignette Survey (2017) (2)
- FRI0154 Incidence of Cancers in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept (2015) (2)
- SAT0408 Both clinical and ultrasonographic evaluation of synovitis are relevant to predict subsequent radiological deterioration in rheumatoid arthritis (2013) (2)
- THU0122 Safety of surgery in patients with rheumatoid arthritis treated by rituximab in routine care: Data from the french air registry (2013) (2)
- Muscle disorders111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study (2012) (1)
- Antibodies to HTLV-I in Sjögren's syndrome. (1995) (1)
- OP0280 Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A Cost-Utility Analysis Based on the Strass Trial (2015) (1)
- [Anatomo-clinical conference. Hôpital Cochin. Case No 3 - 1995. Apropos of destructive oligoarthritis]. (1995) (1)
- FRI0219 Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in The French Registry Regate (Registry –Roactemra) (2016) (1)
- AB0461 Experience with subcutaneous abatacept in routine clinical practice: 6-month interim analysis of a 2-year, prospective, non-interventional, multicentre study in patients with ra (2018) (1)
- Compendium on Rheumatic Diseases (2009) (1)
- OP0176 Rna sequencing detection of gene dysregulation in b cells sorted from salivary gland tissue and peripheral blood reveals new pathways involved in sjÖgren’s syndrome pathophysiology (2018) (1)
- Big Data International Primary Sjogren Syndrome Registry : Baseline Characterization and Diagnostic Approach in 6047 Patients Fulfilling the 2002 AE Criteria (2015) (1)
- LYMPHOID NEOPLASIA Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sj¨ogren ’ s syndrome (2013) (1)
- Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update (2022) (1)
- Comparison of modified disease-activity scores with original composite scores for prediction of structural damages in rheumatoid arthritis: Data from the ESPOIR cohort. (2017) (1)
- Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study (2022) (1)
- [Microangiopathic hemolytic anemia in cancers. A case with remission after chemotherapy]. (1988) (1)
- The BAFF/APRIL System in Autoimmunity (2009) (1)
- Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts (2022) (1)
- Tocilizumab in Treatment for Patients With COVID-19-Reply. (2021) (1)
- FRI0221 Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action? (2017) (1)
- Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach (2020) (1)
- The Role of Rare Protein-Coding Variants in Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis (2017) (1)
- Two-Year Abatacept Retention Rate in Clinical Practice in the French ACTION Cohort. (2019) (1)
- OP0094 DKK1 serum level is increased in recent spondyloarthritis and is associated with higher prevalence of syndesmophytes. Data from the desir cohort (2013) (1)
- Systemic Sjögren presenting without sicca syndrome : characterization of 240 patients according to the new 2017 ACR/EULAR Classification Criteria (2018) (1)
- A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort (2020) (1)
- Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis. (2022) (1)
- Autoantibodies sequencing may help to understand the physiopathology of some monoclonal lymphoid proliferations and autoimmune diseases. (1994) (1)
- Authors' Response to Tezcan and Colleagues' Letter to the Editor (2017) (1)
- Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design (2022) (1)
- OP0227 A Randomized Double-Blind Treatment Strategy Study Evaluating Continuation or Reduced-Frequency Dosing of Certolizumab Pegol versus Withdrawal To Maintain Low Disease Activity in Early RA Patients (C-Early Period 2) (2016) (1)
- [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease]. (2006) (1)
- Risedronate-induced rhabdomyolysis in a patient with inflammatory myopathy. (2020) (1)
- EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint disease. (2007) (1)
- FRI0110 The impact of seropositivity on the effectiveness of abatacept versus tnf inhibitors in rheumatoid arthritis. real life data from several european registries (THE PAN-ABA STUDY) (2018) (1)
- POS0096 SJÖGREN’S DISEASE AND SYSTEMIC LUPUS ERYTHEMATOSUS DDX6-CXCR5 RISK INTERVALS REVEAL COMMON SNPS WITH FUNCTIONAL SIGNIFICANCE IN IMMUNE AND SALIVARY GLAND CELLS (2022) (1)
- Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma. (2022) (1)
- POS1212 SARS-CoV-2 VACCINE SAFETY IN ADOLESCENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES AND ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS (2022) (1)
- Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. (2022) (1)
- Differences in abatacept use in rheumatoid arthritis patients across Europe: A Pan-European database analysis of abatacept in European RA registries (2013) (1)
- Multiple myeloma with loss of CD138 expression in two rare metastatic localizations, peritoneum and skin (2007) (1)
- [Renal involvement in Sjögren's syndrome]. (2020) (1)
- POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY (2021) (1)
- Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study (2022) (1)
- SAT0379 Is Fatigue Immune-Mediated in Primary SjÖgren's Syndrome? Data from the Prospective Assess Cohort (2015) (1)
- THU0082 Comparison of M-DAS and DAS28, Two Composite Scores for Prediction of Structural Damages in Early Arthritis: Data from the Espoir Cohort (2015) (1)
- OP0265 COMPARISON OF THE EFFECT OF DIFFERENT JANUS KINASE INHIBITORS ON ACTIVATION, FUNCTION AND PROPERTY OF NK CELLS TO CONTROL CANCER CELL LINES PROLIFERATION: AN EX VIVO AND IN VITRO STUDY. (2022) (1)
- Associations between ocular and extra-ocular assessment in primary Sjögren's syndrome. (2022) (1)
- 18F-FDG PET/CT and MRI findings of Shulman syndrome also known as eosinophilic fasciitis (2021) (1)
- Genetic Variants of TNFAIP3 in Patients with HCV Related Lymphoma Are Associated with the Presence of Rheumatoid Factor (RF) (2014) (1)
- CTLA-4 polymorphism and primary Sjögren's syndrome: authors' response (2007) (1)
- Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases) (2022) (1)
- POS0095 DEVELOPPING A SCORE TO PREDICT PRECLINICAL INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS – A CROSS-SECTIONAL STUDY FROM THE ESPOIR COHORT (2021) (1)
- AB0310 TROUGH CONCENTRATION AND ESTIMATED CLEARANCE CAN DETECT IMMUNOGENICITY TO ADALIMUMAB IN RA PATIENTS: A PROSPECTIVE LONGITUDINAL MULTICENTRE STUDY (2020) (1)
- FRI0246 Serious infusion-related reactions after rituximab in patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry (2013) (1)
- [Medical treatment of radicuralgia caused by posterior interapophyseal synovial cysts. 7 cases]. (1990) (1)
- OP0180 IMPACT OF RF AND ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS ON 2-YEAR RETENTION OF ABATACEPT IN PATIENTS WITH RA (2021) (1)
- OP0126 LYMPHOMA ARISING AT THE TIME OF DIAGNOSIS OF PRIMARY SJÖGREN SYNDROME: A HIGHLY-ACTIVE SYSTEMIC SUBSET OF THE DISEASE (2019) (1)
- SAT0324 ARTICULAR MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB (2019) (1)
- FRI0100 TOWARDS THE LOWEST EFFICACIOUS DOSE (TOLEDO): RESULTS OF A MULTICENTER NON-INFERIORITY RANDOMIZED OPEN-LABEL CONTROLLED TRIAL ASSESSING TOCILIZUMAB OR ABATACEPT INJECTION SPACING IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION (2019) (1)
- THU0271 PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES (2020) (1)
- Using genetics to predict toxicity of cancer immunotherapy (2022) (1)
- OP0054 High-Throughput DNA Methylation Analysis of Cell Sorted Blood Cell Populations Reveals Widespread Epigenetic Deregulation in Sjogren’s Syndrome (2013) (1)
- [Severe hemolytic anemia in angio-immunoblastic lymphadenopathy. Value of intravenous immunoglobulins]. (1990) (1)
- [Antibody activities of monoclonal immunoglobulins]. (1993) (1)
- Comment on: Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease? Reply. (2019) (1)
- Inflammation-targeted therapies and Cancer. (2021) (1)
- Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells (2022) (1)
- P071/O13 RNA sequencing detection of gene dysregulation in B cells sorted from salivary gland tissue and from peripheral blood reveals new pathways involved in primary sjÖgren’s syndrome pathophysiology (2018) (1)
- Sjögren's syndrome and virus. (1995) (1)
- Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers. (2016) (1)
- Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis (2022) (1)
- THU0681 Baseline ESSDAI/DAS scores in 8061 patients with primary sjÖgren syndrome: characterization of systemic disease (2017) (1)
- Immune-related adverse events of cancer immunotherapies targeting kinases. (2022) (1)
- Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29]. (2017) (1)
- Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis (2017) (1)
- Complex Functional Effects Within The HLA Contribute To Sjogren's Syndrome Pathogenesis and May Influence Both Transcriptional Regulation and Peptide Binding. (2013) (0)
- AB0111 Membrane tnf expression on monocytes and differentiation of monocytes into m2-m1 macrophages: 2 new biomarkers of rheumatoid arthritis (2018) (0)
- SAT0399 Chronic Antigenic Stimulation and Activity of the Disease Are Predictive of Lymphoma Development in Primary SjÖgren Syndrome: A Case Control Study of 64 Cases (2015) (0)
- FRI0048 Prevalence of Tuberculosis in Early Arthritis and Early Spondyloarthritis Increased in Comparison to the General Population - Results from the ESPOIR and DESIR Cohorts (2014) (0)
- POS0447 PHYSICAL FUNCTION IN PATIENTS WITH RA, STRATIFIED BY SEROSTATUS AND TREATMENT LINE, FOLLOWING SC ABATACEPT: POST HOC ANALYSIS OF AN OBSERVATIONAL, 2-YEAR STUDY CONDUCTED IN ROUTINE CLINICAL PRACTICE (ASCORE) (2021) (0)
- AB0440 The Impact of Patient Characteristics and Past Treatment History on the Evolution of Functional Disability in RA Patients Treated with Abatacept. A Pan-European Analysis of RA Registries (2015) (0)
- THU0322 Altered Quality of Life Is Mainly Associated with Patient Reported Outcomes in Primary Sjögren's Syndrome Patients: Data from A Large Therapeutic Trial (2016) (0)
- Evaluation of Liver Gene Therapy by Lentiviral Vectors in a Dog Model of Hemophilia B (2012) (0)
- THU0151 RISK OF MALIGNANCIES ASSOCIATED WITH CS DMARDS IN RHEUMATOID ARTHRITIS: COMPARISON WITH GENERAL POPULATION AND BIOLOGIC TREATED PATIENTS (ANALYSIS OF A NATIONAL CLAIM DATABASE) (2020) (0)
- P028 Treatment of BAFF transgenic mice with ANTI-TNF: monoclonal ANTI-TNF are associated with a higher risk of lymphoma than etanercept (2017) (0)
- [Acute anterior uveitis and psoriatic rheumatism. 2 cases and a review of the literature]. (1989) (0)
- THU0395 Low Numbers of Blood and Salivary Natural Killer Cells are Associated with a Better Response to Belimumab in Primary Sjogren's Syndrome: Results of the Beliss Study (2015) (0)
- P008 Methotrexate and baff interaction prevents immunisation against TNF-Α inhibitors by increasing adenosine and regulatory B-cells (2018) (0)
- [Tuberculoid tenosynovitis of the hand. Apropos of 3 cases of unusual and various causes]. (1991) (0)
- Creation Date : December 2002 Update : February 2005 Scientific (2005) (0)
- Error in the Abstract in the Article by Maldini et al (Arthritis Care Res [Hoboken], March 2014) (2014) (0)
- Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? – Authors' reply (2022) (0)
- [Treatment of peripheral neuropathies associated with IgM anti-myelin monoclonal gammopathy]. (1996) (0)
- THU0107 CCL19, a chemokine involved in B-cell trafficking, is related to the decrease of blood memory B-cells and predicts the clinical response to rituximab in rheumatoid arthritis: Results from the smart study (2013) (0)
- Renal involvement of lymphomas proven by kidney biopsy: report of 10 cases from a tertiary care center and comparison with the literature (2022) (0)
- AB1131 IDENTIFICATION OF FACTORS ASSOCIATED WITH THE OCCURRENCE OF SEVERE FORMS OF COVID-19 INFECTION IN PATIENTS WITH AUTOIMMUNE/INFLAMMATORY RHEUMATIC DISEASES (2022) (0)
- FRI0179 anti-TNF Therapy Is Associated with An Impaired Function of Nk Cells and A Defective Immunosurveillance against B-Cell Lymphomas (2016) (0)
- Case Reports1. A Late Presentation of Loeys–Dietz Syndrome: Beware of TGFβ Receptor Mutations in Benign Joint Hypermobility (2013) (0)
- SAT0171 Serum IL-33 Independently Predicts Response To Rituximab in Rheumatoid Arthritis: Data from The Smart and Replication Cohorts (2016) (0)
- Hyperosmolar environment and salivary gland epithelial cells increase extra-cellular matrix remodeling and lymphocytic infiltration in Sjögren's syndrome. (2023) (0)
- Clinical and immunological disease patterns of primary Sjogren syndrome driven by gender and age at diagnosis (2018) (0)
- OP0080 CXCL13 and CCL11 Serum Levels are Associated With Lymphoma Occurrence and Disease Activity in Primary Sjögren Syndrome: Data from the French Prospective Cohort Assessment (2015) (0)
- SAT0052 Is Information about The Reason for Previous Biologics Discontinuation Useful To Predict The Effectiveness of A Biologic with A Different Mode of Action? (2016) (0)
- SAT0112 Prevalence and incidence over 3 years of different comorbidities in rheumatoid arthritis (RA): a 3 year longitudinal study in 769 established ra patients (2017) (0)
- THU0277 HOW THE AGE AT DIAGNOSIS MODIFIES THE PHENOTYPE OF PRIMARY SJÖGREN SYNDROME: ANALYSIS IN 11,420 PATIENTS (BIG DATA SJÖGREN PROJECT) (2019) (0)
- Excessive FMS-like tyrosine kinase3-ligand heralds lymphoma in primary sjögren's syndrome (2011) (0)
- FRI0704-HPR Sesame quiz: a playful online questionnaire to assess patients’ knowledge about sjogren’s syndrome (2018) (0)
- AB0190 CROSSTALK BETWEEN SALIVARY GLAND EPITHELIAL CELLS AND B LYMPHOCYTES IN PRIMARY SJÖGREN’S SYNDROME (2019) (0)
- [Pathophysiological advances underlying the biotherapeutic revolution in inflammatory rheumatism]. (2012) (0)
- AB0412 Less than 5% of real-life patients who switch from iv to sc abatacept in real-world clinical practice subsequently switch back to the iv formulation (2017) (0)
- SAT0114 Prevalence of Cardiovascular Comorbidities Already Increased at Onset of Arthritis and Axial Spondyloarthritis - Results from the ESPOIR and DESIR Cohorts (2014) (0)
- Manifestations inhabituelles révélant un myélome multiple (2007) (0)
- THU0358 Usefulness of 18f-fdg positron emission tomography (PET) for lymphoma diagnosis in patients with primary sjÖgren’s syndrome (2018) (0)
- THU0679 ADHERENCE TO THE MEDITERRANEAN DIET AND RISK OF RHEUMATOID ARTHRITIS IN THE FRENCH PROSPECTIVE E3N COHORT STUDY (2019) (0)
- OP0181 CURRENT FAVOURABLE 10-YEAR OUTCOME OF PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: DATA FROM THE ESPOIR COHORT (2021) (0)
- POS1227 TIME BETWEEN SECOND AND THIRD DOSES INFLUENCES RESPONSE TO COVID-19 VACCINE IN AUTO-IMMUNE DISEASE PATIENTS TREATED WITH RITUXIMAB WITHOUT RESPONSE TO TWO DOSES. (2022) (0)
- POS1429 IMPROVING ACCURACY OF SELF-REPORTED DIAGNOSES OF POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS IN THE FRENCH PROSPECTIVE E3N COHORT: A VALIDATION STUDY (2022) (0)
- SAT0208 Inflammatory Myopathies Associated with Sjögren's Syndrome Do Not Differ from Those without Sjögren's Syndrome Aside from Older Age at Diagnosis and Less Frequent Normal Muscle Biopsy (2016) (0)
- THU0152 Who are the patients with rheumatoid arthritis (RA) who are getting comorbidity screening procedures in accordance with guidelines? a study of 769 established ra patients (2017) (0)
- [Retrosomatic fissure, bilateral isthmic lysis and spina bifida occulta]. (1989) (0)
- [Paralysis of the posterior branch of the radial nerve caused by a lipoma]. (1987) (0)
- Lifetime female hormonal exposure and risk of rheumatoid arthritis in postmenopausal women: results from the French E3N cohort. (2022) (0)
- NeutraSal ® is clinically proven to help restore the oral environment 2 FOR PATIENTS WITH SJÖGREN ’ S SYNDROME 90 % OF PATIENTS REPORTED IMPROVEMENT IN SWALLOWING (2017) (0)
- FRI0273 Rna sequencing detection of gene dysregulation in epithelial sorted cells from salivary gland tissue reveals interesting pathways involved in sjÖgren’s syndrome pathophysiology (2018) (0)
- Author Correction: Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells (2023) (0)
- OP0286 DEVELOPMENT AND PRELIMINARY VALIDATION OF THE SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR): A CONSENSUAL COMPOSITE SCORE FOR ASSESSING TREATMENT EFFECT IN PRIMARY SJÖGREN’S SYNDROME (2022) (0)
- Error in Sample Size. (2021) (0)
- CTLA-4 + 49 A / G and CT 60 gene polymorphisms in primary Sjögren syndrome (2015) (0)
- FRI0155 Fifty Percent of Patients Who Tapered TNF-Blockers while in Stable Remission Are Able To Maintain A Tapered Regimen at 3 Year: Long Term Follow-Up Extension of The Strass Trial (2016) (0)
- SSF Clinical Practice Guidelines for Caries Prevention are Here ! (2016) (0)
- SAT0501 Prevalence of hand osteoarthritis in a model of auto-immune disease, sjÖgren syndrome: results of a prospective study (2017) (0)
- FRI0081 A macaque model of rheumatoid arthritis by immunization with citrullinated peptides: lessons for the human disease (2017) (0)
- [Lyme disease, a new etiology of prolonged fever]. (1990) (0)
- FRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial (2013) (0)
- Iconography : Physiopathologie du syndrome de Gougerot-Sjögren (2010) (0)
- Use of Phenol Red Thread Test as a rescue test in diagnostic strategy of severe ocular syndrome (2010) (0)
- AB0150 Understanding The Role of The IL12/iL35 Balance in Sjögren Syndrome (2016) (0)
- AB0460 Remission After Discontinuation of Abatacept for Good Response: Results from the ORA Registry (2015) (0)
- Tocilizumab Plus Dexamethasone in Patients with Moderate-to-Severe COVID-19 Pneumonia: a Randomized Clinical Trial of the CORIMUNO-19 Study Group (2021) (0)
- Response to «Are Salivary Gland Epithelial Cells the Main Source of Increased IL-7 in Primary Sjögren's Syndrome?» by Caiqun Chen et al. (2021) (0)
- POS0107 ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIES (2022) (0)
- AB0173 Metabolomics in Primary SjÖgren's Syndrome: Data from the Assess Cohort (2015) (0)
- How the different systemic organ involvements are overlapped in patients with primary Sjogren syndrome: analysis using a mathematical model (2018) (0)
- CTLA-4 + 49 A / G and CT 60 gene polymorphisms in primary Sjögren syndrome (2015) (0)
- [Involvement of the cranial nerves in IgM monoclonal dysglobulinemia with antimyelin antibody activity]. (1989) (0)
- JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis (2019) (0)
- O07. First Results of a European Registries Collaborative Project to Describe the Spectrum of Lymphomas Across Different Drug Treatment Groups in Rheumatoid Arthritis (2015) (0)
- SAT0001 Identification of Sjögren's Syndrome Risk Loci near TNFAIP3 and PRDM1 (2016) (0)
- POS0512 ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTING (2022) (0)
- Janus kinase inhibitors alter NK cells phenotype and inhibit their antitumor capacity. (2022) (0)
- FRI0607 IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET (2019) (0)
- Reply: To PMID 25779552. (2015) (0)
- AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTING (2021) (0)
- P021 Membrane TNF expression on monocytes and differentiation of monocytes into M2-M1 macrophages: 2 new biomarkers of rheumatoid arthritis (2018) (0)
- [How to differentiate between useful and useless drugs?]. (2012) (0)
- OP0186 Analysis of Anti Porphyromonas Gingivalis (PG) Antibodies in a Large Cohort of Patients with an Early Arthritis (ESPOIR) (2013) (0)
- Comparison of Ocular Dryness Between Patients Affected by Sjögren Patients and Those Affected by SAPS (Sicca Asthenia Polyalgia Syndrome) (2006) (0)
- FRI0070 Trajectories of Disease Activity in Rheumatoid Arthritis Patients after Abatacept Initiation and Their Association with Clinical Characteristics (2016) (0)
- OP0307 Treatment of baff transgenic mice with ANTI-TNF: monoclonal ANTI-TNF are associated with a higher risk of lymphoma than etanercept (2017) (0)
- Impact of patient ancestry on heterogeneity of Sjögren’s disease (2023) (0)
- AB0175 In early rheumatoid arthritis, elevated serum levels of ifn-regulated chemokines are associated with disease activity, autoantibody secretion and radiographic progression (2013) (0)
- 080 Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with Rheumatoid Arthritis who are Biologic Naive: 6-Month Results from a Real-World, International, Prospective Study (2016) (0)
- [Sjögren's syndrome pathophysiology]. (2010) (0)
- O017 Il-7 in primary sjÖgren syndrome (PSS) is secreted by salivary gland epithelial cells after ifn stimulation and is associated with B-cell activation (2018) (0)
- SAT0244 Association Between Spondyloarthritis and Takayasu Arteritis: a Study of 14 Cases (2015) (0)
- AUTO-IMMUNITE ET VIRUS (1999) (0)
- [Pitié-Salpêtriére Hospital. Case 1--1998. Acute renal failure with large kidneys in a patient with Sjögren syndrome]. (1998) (0)
- THU0264 In Early Rheumatoid Arthritis (Espoir Cohort), Serum CCL19 Level is Associated with Disease Activity, Autoantibody Secretion and 3-Year Radiographic Progression: Data from the Espoir Cohort (2014) (0)
- Reply (2016) (0)
- AB1450 CHARACTERISTICS, OUTCOME AND FACTORS ASSOCIATED WITH EVOLUTION TO MULTIPLE MYELOMA AND SURVIVAL IN PATIENTS WITH SOLITARY BONE PLASMACYTOMA. (2022) (0)
- OP0012 ASSOCIATION BETWEEN PASSIVE SMOKING IN CHILDHOOD AND ADULTHOOD, AND RHEUMATOID ARTHRITIS: RESULTS FROM THE FRENCH E3N-EPIC COHORT STUDY (2021) (0)
- FRI0180 Multiple sclerosis risk-alleles study in patients with demyelinating side effects on anti tnf alpha therapy (2017) (0)
- THU0686 EARLY MENOPAUSE AND/OR DURATION OF MENOPAUSAL HORMONAL TREATMENT MAY INCREASE THE RISK OF RHEUMATOID ARTHRITIS IN TOBACCO EXPOSED WOMEN: RESULTS OF THE E3N COHORT (2019) (0)
- Reply (2015) (0)
- Optimization of the Phenol Red Thread Test for Assessment of Ocular Dryness in Sjögren’s Syndrome (2005) (0)
- THU0478 Genome-Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with TNF Inhibitors (2014) (0)
- OP0139 FUNCTIONAL EVALUATION OF THE SJÖGREN’S SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS DDX6-CXCR5 RISK INTERVAL (2020) (0)
- Analysis of anti Porphyromonas gingivalis (P. gingivalis) antibodies in a large cohort of patients with an early arthritis (ESPOIR) (2013) (0)
- OP0023 Germinal and Somatic Genetic Variants of TNFAIP3 Promote Lymphomagenesis Process Complicating Primary Sjögren’s Syndrome (2013) (0)
- [Antibody activity of monoclonal immunoglobulins]. (1988) (0)
- AB0133 Blood Transfusion (BT) is Associated with the Risk of Developing Rheumatoid Arthritis (RA) and with Disease Severity: Data from ESPOIR Cohort (2014) (0)
- resolve the long debate on the issue syndrome : we actually need to definitively Classification criteria for Sjögren ' s (2013) (0)
- Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach. (2022) (0)
- Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF (2020) (0)
- Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients. (2021) (0)
- Potential Of Integrating Human Genetics and Electronic Medical Records For Drug Discovery : The Example Of TYK2 and Rheumatoid Arthritis (2013) (0)
- OR.104. Association of Sjögren's Syndrome (SS) and Systemic Lupus Erythematosus (SLE) with BLK (2008) (0)
- Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein e Barr virus (0)
- Maintien à 3 ans de la stratégie de décroissance des anti-TNF dans la polyarthrite rhumatoïde : suivi de l’étude randomisée et contrôlée STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) (2016) (0)
- Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study (2019) (0)
- AB0679 One third of primary sjÖgren syndrome (PSS) patients with anti-CCP develop erosive rheumatoid arthritis (RA) after a 5-year follow-up (2013) (0)
- Anthropometric Measures and Risk of Rheumatoid Arthritis in the French E3N Cohort Study (2022) (0)
- AB0335 Are eular rheumatoid arthritis (RA) management recommendations applicable at the country level? similarities and differences with the recent french ra management recommendations (2018) (0)
- Certolizumab, an anti-TNF safe during pregancy? The CRIB Study results: an interview with Professor Xavier Mariette. (2017) (0)
- AB0267 Treatment paradigms in real-world practice: biologic agent use prior to and after discontinuation of abatacept in the action study (2017) (0)
- P111 Exploratory Analysis of Filgotinib Safety Data in Patients With Moderately to Severely Active Rheumatoid arthritis and an Increased Risk of Cardiovascular Events: Data From Phase 2 and 3 Clinical Trials (2023) (0)
- SAT0400 Epidemiological Aspects of Neurological Impairment in SjÖgren's Syndrome, Data from the Assess French Cohort (2015) (0)
- Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective. (2022) (0)
- Assessment of Relationships between Subjective and Objective Signs of Ocular Dryness in Sjögren Syndrome (2003) (0)
- Review Lymphomas complicating primary Sjo¨gren’s syndrome: from autoimmunity to lymphoma (2021) (0)
- AB0462 IMMUNIZATIONTO RITUXIMAB IS MORE FREQUENT IN AUTOIMMUNE SYSTEMIC AUTOIMMUNE DISEASES THAN IN RHEUMATOID ARTHRITIS AND MAY BE MANAGED BY SWITCHING FROM RITUXIMAB TO OFATUMUMAB (2019) (0)
- Looking into the Future—The EULAR Disease Activity Scores: Toward a Consensual Evaluation of Primary Sjogren’s Syndrome (2011) (0)
- Characterisation of the coexistence between sarcoidosis and Sjögren's syndrome. Analysis of 43 patients. (2022) (0)
- SAT0226 MINOR SALIVARY GLAND BIOPSY TO DIAGNOSE LYMPHOMA IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (2020) (0)
- Reply (2022) (0)
- Infections et anti-TNF : le point en 2007 (2007) (0)
- SAT0429 How phenotype of the small fibre neuropathy (SFN) in primary sjÖgren syndrome (PSS) differs from others causes of small fibre neuropathy? (2018) (0)
- AB0204 Glucocorticoid-Sparing Effects of Abatacept in Rheumatoid Arthritis Are Associated with both Abatacept Effectiveness and Seropositivity (2016) (0)
- POS0478 ASSOCIATION BETWEEN BODY SHAPES AND BODY SHAPE TRAJECTORIES, AND THE RISK OF RHEUMATOID ARTHRITIS IN THE FRENCH E3N COHORT (2021) (0)
- University of Groningen Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR) Seror, (2022) (0)
- POS0543 MACHINE LEARNING PREDICTS RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS: RESULTS ON THE ESPOIR, t-REACH AND LEIDEN COHORTS (2022) (0)
- A Genetic Association Test Accounting for Skewed X-Inactivation With Application to Biotherapy Immunogenicity in Patients With Autoimmune Diseases (2022) (0)
- Treatment of BAFF Transgenic Mice with Anti-TNF: Monoclonals Are Associated with a Higher Risk of Lymphoma Than Etanercept (2016) (0)
- Response to « Rheumatoid factor in Sjögren's syndrome: The need to target MALT tissue for preventing lymphoma » (2016) (0)
- Identification of Novel Sjogren's Syndrome Risk Loci in the Regions of TNFAIP3 and PRDM1 (2015) (0)
- [Immunopathology of Gougerot-Sjogren syndrome]. (2001) (0)
- Clinical and Immunological Characterization at Diagnosis of 5041 Patients with Primary Sjogren Syndrome Fulfilling the 2002 AE Classification Criteria: The Big Data International Sjogren Project (2015) (0)
- AB1017 ANTI RANK LIGAND IN ACUTE CHARCOT NEURO-OSTEOATHROPATHY OF THE FOOT: A PROMISING TREATMENT (2020) (0)
- P61 SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry (2022) (0)
- THU0163 Early Response as A Predictor of Long-Term Clinical Response in DMARD-Naïve Patients with Severe, Active and Progressive RA Treated with Certolizumab Pegol plus Optimized MTX versus Optimized MTX Alone (2016) (0)
- AB0444 Impact of Gender on the Response and the Tolerance to Treatment with Abatacept in RA Patients: Results from the “Orencia and Rheumatoid Arthritis” Registry (2015) (0)
- OP0218 Elevated Serum BAFF is Associated with an Increased Risk of Developing A New Systemic Complication: Data from the Prospective ASSESS Cohort (2014) (0)
- Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma. (2023) (0)
- Errors in Group Information Supplement. (2021) (0)
- POS0748 COMPARISON BETWEEN PRIMARY SJÖGREN’S SYNDROME PATIENTS WITH AND WITHOUT DRYNESS (2022) (0)
- FRI0482 Cost effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before anti-tnf therapy (2013) (0)
- Prevalence of hand osteoarthritis in a model of auto-immune disease, Sjögren syndrome: results of a prospective study (2017) (0)
- Bruton's tyrosine kinase (BTK) gene overexpression is associated with risk of lymphoma in primary Sjögren's syndrome. (2023) (0)
- POS0322 CARDIOVASCULAR RISK FACTORS AND RISK OF GIANT CELL ARTERITIS AND/OR POLYMYALGIA RHEUMATICA: RESULTS FROM THE FRENCH E3N COHORT STUDY (2022) (0)
- THU0352 Worldwide Heterogeneous Diagnostic Approach To Primary Sjögren Syndrome in 8315 Patients (EULAR-SS Task Force Big Data Sjögren Project) (2016) (0)
- Cl in ic ian ’ s Corner Systemic Activity at Diagnosis of Sjögren ’ s : A Key Prognostic Marker (2015) (0)
- CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases (2023) (0)
- 3-year prospective study in France Lymphomas in rheumatoid arthritis patients treated with methotrexate: a (2013) (0)
- Clinical significance of a self-reported familial occurrence of rheumatoid arthritis among patients with recent-onset arthritis: data from the ESPOIR cohort. (2022) (0)
- Characterization of Baseline Systemic Activity Using the New ClinESSDAI in the Big Data Sjogren Project Cohort: Analysis in 3316 Patients (2015) (0)
- POS0700 IMPACT OF DELAYING INITIATION OF METHOTREXATE BY 1 MONTH ON THE OUTCOME OF RHEUMATOID ARTHRITIS AT 1 YEAR (2022) (0)
- OP0237 Polymorphisms of Gene Implicated in Type 1 Interferon Pathway Are Associated with The Clinical Response of Rituximab at 24 Weeks in Rheumatoid Arthritis (2016) (0)
- and discussion of its significance. Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases (2017) (0)
- Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET (2022) (0)
- Hepatis C virus related non-Hodgkin’s lymphomas (2000) (0)
- The Professionals ’ Resource on Sjögren ’ s Syndrome First Genetic Associations Established for Sjögren ’ s (2014) (0)
- DKK1 Serum Level Is Increased in Recent Spondyloarthritis and Is Associated with Higher Prevalence of Syndesmophytes. Sclerostin Is Highly Correlated with Age. Data From the DESIR Cohort (2012) (0)
- Clinically effective concentration and risk of hydroxychloroquine retinopathy in systemic lupus erythematosus: walking on a thin line. Comment on the article by Garg et al (2021) (0)
- FRI0344 Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the french nationwide cryovas survey (2013) (0)
- SAT0044 Five-Year Favourable Outcome of Patients with Early Rheumatoid Arthritis in the 2000S: Data from the Espoir Cohort (2013) (0)
- SAT0088 First year rapid radiological progression is the best predictor of further progression in early arthritis: Results of the ESPOIR cohort (2013) (0)
- 07.01 A multi-parameter response prediction model for rituximab in rheumatoid arthritis (2017) (0)
- Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice (2020) (0)
- SAT0605 BODY MASS INDEX AND SYSTEMIC CORTICOSTEROID USE AS INDICATORS OF DISEASE BURDEN AND THEIR INFLUENCE ON THE SAFETY PROFILE OF CERTOLIZUMAB PEGOL ACROSS INDICATIONS (2019) (0)
- The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection (2023) (0)
- FRI0152 Active therapeutic immunization with TNF-kinoid in rheumatoid arthritis patients with secondary resistance to tnfα antagonists is safe and immunogenic (2013) (0)
- Performance of the EULAR/ACR 2019 Classifi cation Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease (2019) (0)
- AB0550 PHENOTYPE OF BIOPSY-PROVEN PATIENTS WITH PRIMARY SJÖGREN SYNDROME LACKING RO AUTOANTIBODIES: HIGH FREQUENCY OF DRYNESS SYMPTOMS WITH LOW SYSTEMIC ACTIVITY (BIG DATA SJÖGREN PROJECT) (2019) (0)
- Evaluating Placental Transfer of Certolizumab Pegol and Polyethylene Glycol During Pregnancy: Results From CRIB, a Prospective, Post-Marketing, Multicenter, Pharmacokinetic Study: 641 (2017) (0)
- Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry RHEUMATOLOGY (2016) (0)
- Assessment of the Cut-off Value of Phenol Red Thread in Ocular Sicca Syndrome (2002) (0)
- SAT0287 Ethnic Differences Strongly Influence The Phenotypic Expression of Primary Sjögren: Study of 7887 Patients from 20 Countries on 5 Continents (EULAR-SS Task Force Big Data Sjögren Project) (2016) (0)
- Care needs to be taken when reviewing malignancy data reported from observational studies: Comment on the article by Onel and Onel (2011) (0)
- AB0123 IMPACT OF TOBACCO ON PRIMARY SJÖGREN SYNDROME: ANALYSIS OF THE FRENCH COHORT ASSESS (2022) (0)
- POS0711 TOLERANCE AND EFFICACY OF TARGETED THERAPIES PRESCRIBED FOR OFF-LABEL INDICATIONS IN REFRACTORY SYSTEMIC AUTOIMMUNE DISEASES: DATA OF THE FIRST 100 PATIENTS ENROLLED IN THE TATA REGISTRY (TARGETED THERAPY IN AUTOIMMUNE DISEASES) (2022) (0)
- Erratum: Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis (2016) (0)
- SLE, Sjögren’s and APS – treatment (2020) (0)
- Is there a seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome? Data from the prospective assess cohort and from 3 randomized controlled trials. (2017) (0)
- The NKp30/B7H6 Axis Contributes To Pathogenesis In Primary Sjogren's Syndrome. (2013) (0)
- Long‐term exposure to monoclonal anti‐TNF is associated with an increased risk of lymphoma in BAFF‐transgenic mice (2021) (0)
- Virus de l’hépatite C, arthrites et arthromyalgies (2003) (0)
- PARADOXICAL RESPONSE IN THE TREATMENT OF TUBERCULOSIS AFTER DISCONTINUATION OF ANTI TNF IN PATIENTS WITH INFLAMMATORY DISEASES: A CASE-SERIES (2011) (0)
- Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis. (2013) (0)
- THU0284 Predicting survival in 6240 patients with primary sjÖgren' syndrome (big data sjÖgren project) (2017) (0)
- SAT0226 Cigarette smoking in pss: association with earlier onset, male sex and serum baff increase in the assess cohort (2013) (0)
- Monoclonal IgMfrompatients withperipheral demyelinating neuropathies cross-react withbacterial polypeptides (1994) (0)
- Looking into the Future—Emerging Therapies Based on Pathogenesis (2011) (0)
- SAT0624 VALIDATION PROCESS OF CASES OF RHEUMATOID ARTHRITIS IN A LARGE PROSPECTIVE COHORT OF FRENCH ADULT WOMEN: THE E3N COHORT (2019) (0)
- Letter to the Editor Perioperative Management of Patients with Rheumatoid Arthritis Treated with TNF- Blocking Agents (2007) (0)
- Response to: ‘Role of interaction between B cells and epithelial cells in pSS’ by Pringle et al (2020) (0)
- Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries (2017) (0)
- Rheumatoid arthritis - treatment 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis (2011) (0)
- Papular mucinosis associated with band acro-osteolysis: a new syndrome associated with connective tissue-disease. (2021) (0)
- SAT0269 Efficacy and Safety of Anti-TNF Alpha in BehÇEt Disease: Preliminary Results of A French Multicenter Registry of 92 Patients (2014) (0)
- SAT0302 Analysis of 9302 patients from the big data international primary sjÖgren syndrome cohort: clinical presentation at diagnosis of european vs non-european patients (2017) (0)
- Characteristics of patients with infectious cryoglobulinemia vasculitis in the absence of HCV infection: Results from the French nationwide CryoVas survey (2013) (0)
- P084 Salivary gland epithelial cells from sjÖgrens’ patients increase B lymphocytes survival and activation (2019) (0)
- Miscellaneous Rheumatic Syndromes (2021) (0)
- FRI0312 Arthritis in primary sjÖgren’s syndrome: characteristics, outcome and treatment from french multicenter retrospective study (2018) (0)
- P034 Presence of a specific defect in M2 polarization of blood monocytes from patients with rheumatoid arthritis, associated with increased microRNA-155 (2019) (0)
- O8 Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease (2020) (0)
- AB0371 Is Switching from IV To SC Abatacept Therapy Sustainable in The Real World? 1-Year Analysis of The Prospective, International Action Study (2016) (0)
- SAT0179 CHANGE IN IMMUNOLOGICAL PARAMETERS DURING FOLLOW-UP OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: DATA FROM THE FRENCH ASSESS COHORT (2019) (0)
- University of Birmingham Efficacy of Epratuzumab, an AntiCD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: (2018) (0)
- Phenol Red Thread Test: Optimisation of Diagnostic Strategy in Severe Ocular Sicca Syndrome (2008) (0)
- AB0477 Retention Rates and Clinical Outcomes in Cohorts of Patients (Biologic Naïve or Failed Prior Biologics) Treated with Intravenous Abatacept in a Real-World Setting: 6-Month Results from the Action Study (2015) (0)
- Incorrect Spelling of Author Name in the Article by Seror et al (Arthritis Care Res [Hoboken], April 2010) (2013) (0)
- OP0125 LYMPHOMAS COMPLICATING RHEUMATOID ARTHRITIS: RESULTS OF A FRENCH MULTI-CENTRE CASE-CONTROL STUDY (2020) (0)
- How ethnicity modifies systemic activity of primary Sjögren syndrome : analysis of baseline ESSDAI scores in a multi-ethnic international cohort (2018) (0)
- POS0692 IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN’S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Xavier Mariette?
Xavier Mariette is affiliated with the following schools:
